Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Pirfenidone

Brand: Esbriet®
NICE TA: 504
Indication: Treating idiopathic pulmonary fibrosis (NICE TA504)
Disease category: Respiratory system
Commissioning responsibility: NHS England
PbR excluded: Yes

Background

Pirfenidone is recommended as an option for treating idiopathic pulmonary fibrosis in adults only if:

• the person has a forced vital capacity (FVC) between 50% and 80% predicted
• the company provides pirfenidone with the discount agreed in the patient access scheme and
• treatment is stopped if there is evidence of disease progression (an absolute decline of 10% or more in predicted FVC within any 12‑month period).

Recommendation

LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

NICE TA504 - Pirfenidone for treating idiopathic pulmonary fibrosis

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red